EA201100425A1 - Производные пиколинамида в качестве ингибиторов киназы - Google Patents

Производные пиколинамида в качестве ингибиторов киназы

Info

Publication number
EA201100425A1
EA201100425A1 EA201100425A EA201100425A EA201100425A1 EA 201100425 A1 EA201100425 A1 EA 201100425A1 EA 201100425 A EA201100425 A EA 201100425A EA 201100425 A EA201100425 A EA 201100425A EA 201100425 A1 EA201100425 A1 EA 201100425A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinase
compositions
pikolinamida
derivatives
kinase inhibitors
Prior art date
Application number
EA201100425A
Other languages
English (en)
Other versions
EA020136B1 (ru
Inventor
Маттью Т. Бергер
Усок Хан
Цзион Лань
Джизель Нишигучи
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201100425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201100425A1 publication Critical patent/EA201100425A1/ru
Publication of EA020136B1 publication Critical patent/EA020136B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

В заявке описаны новые соединения, композиции и способы ингибирования активности провирусной интеграции киназы Мэлони (киназы PIM), связанные с онкогенезом у человека или животного. В некоторых вариантах осуществления соединения и композиции эффективны для ингибирования активности по меньшей мере одной киназы PIM. Новые соединения и композиции можно использовать по отдельности или в комбинации по меньшей мере с одним дополнительным средством, предназначенным для лечения нарушения, опосредуемого серин/треонинкиназой или рецепторной тирозинкиназой, такого как рак.
EA201100425A 2008-09-02 2009-08-31 Производные пиколинамида в качестве ингибиторов киназы EA020136B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9366608P 2008-09-02 2008-09-02
US22566009P 2009-07-15 2009-07-15
PCT/EP2009/061205 WO2010026124A1 (en) 2008-09-02 2009-08-31 Picolinamide derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201100425A1 true EA201100425A1 (ru) 2011-10-31
EA020136B1 EA020136B1 (ru) 2014-08-29

Family

ID=41228825

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100425A EA020136B1 (ru) 2008-09-02 2009-08-31 Производные пиколинамида в качестве ингибиторов киназы

Country Status (39)

Country Link
US (4) US8329732B2 (ru)
EP (1) EP2344474B1 (ru)
JP (2) JP5412519B2 (ru)
KR (1) KR101345920B1 (ru)
CN (3) CN102203079B (ru)
AU (1) AU2009289319C1 (ru)
BR (1) BRPI0918268B1 (ru)
CA (1) CA2734415C (ru)
CL (1) CL2011000454A1 (ru)
CO (1) CO6351725A2 (ru)
CR (1) CR20110114A (ru)
DK (1) DK2344474T3 (ru)
DO (1) DOP2011000067A (ru)
EA (1) EA020136B1 (ru)
EC (1) ECSP11010859A (ru)
ES (1) ES2551900T3 (ru)
GE (1) GEP20135849B (ru)
HK (2) HK1156627A1 (ru)
HN (1) HN2011000629A (ru)
HR (1) HRP20151410T1 (ru)
HU (1) HUE026381T2 (ru)
IL (1) IL211291A (ru)
MA (1) MA32684B1 (ru)
ME (1) ME01291A (ru)
MX (1) MX2011002365A (ru)
MY (1) MY150136A (ru)
NI (1) NI201100052A (ru)
NZ (1) NZ591449A (ru)
PE (1) PE20110298A1 (ru)
PL (1) PL2344474T3 (ru)
PT (1) PT2344474E (ru)
RS (1) RS54506B1 (ru)
SI (1) SI2344474T1 (ru)
SM (1) SMT201600005B (ru)
SV (1) SV2011003849A (ru)
TW (1) TWI434843B (ru)
UY (1) UY32085A (ru)
WO (1) WO2010026124A1 (ru)
ZA (1) ZA201101118B (ru)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
US20140249135A1 (en) * 2007-03-01 2014-09-04 Novartis Ag Pim kinase inhibitors and methods of their use
EP3495369B1 (en) 2007-06-13 2021-10-27 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
PT2344474E (pt) 2008-09-02 2015-12-28 Novartis Ag Derivados de picolinamida como inibidores de cinase
EP2342190A1 (en) * 2008-09-02 2011-07-13 Novartis AG Bicyclic kinase inhibitors
MX2011012262A (es) 2009-05-22 2012-01-25 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
EP2556066B1 (en) * 2010-04-07 2016-10-19 F.Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
WO2012004217A1 (en) * 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
BR112013012502A2 (pt) 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9284270B2 (en) 2011-02-14 2016-03-15 The Governers Of The University Of Alberta Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids
JP2014506915A (ja) * 2011-03-04 2014-03-20 ノバルティス アーゲー キナーゼ阻害剤としての四置換シクロヘキシル化合物
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
MX2013012661A (es) 2011-04-29 2014-03-27 Amgen Inc Compuestos de piridazina biciclicos como inhibidores pim.
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
US9458151B2 (en) * 2011-08-11 2016-10-04 Jikai Biosciences, Inc. Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
US9453003B2 (en) * 2011-08-11 2016-09-27 Jikai Biosciences, Inc. Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2013175388A1 (en) * 2012-05-21 2013-11-28 Novartis Ag Novel ring-substituted n-pyridinyl amides as kinase inhibitors
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
PL2900657T3 (pl) 2012-09-26 2020-07-27 F.Hoffmann-La Roche Ag Cykliczne związki eterowe pirazol-4-ilo-heterocyklilo-karboksyamidu i sposoby stosowania
CN103724301A (zh) * 2012-10-10 2014-04-16 上海特化医药科技有限公司 (2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
JP6437452B2 (ja) * 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
EA030705B1 (ru) 2013-03-06 2018-09-28 Инсайт Холдингс Корпорейшн Способы и промежуточные соединения при получении ингибитора jak
US9113629B2 (en) * 2013-03-15 2015-08-25 Dow Agrosciences Llc 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides
ES2792549T3 (es) 2013-08-07 2020-11-11 Incyte Corp Formas de dosificación de liberación sostenida para un inhibidor de JAK1
WO2015019320A1 (en) * 2013-08-08 2015-02-12 Novartis Ag Pim kinase inhibitor combinations
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US20160375024A1 (en) * 2013-11-27 2016-12-29 Novartis Ag Combination therapy comprising an inhibitor of jak, cdk, and pim
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106103484B (zh) 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
MX2016012007A (es) 2014-03-18 2016-12-05 Hoffmann La Roche Compuestos de oxepan-2-il-pirazol-4-il-heterociclil-carboxamida y metodos de uso.
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
MY190404A (en) 2015-03-10 2022-04-21 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
CN105254624B (zh) * 2015-09-18 2019-08-09 上海吉铠医药科技有限公司 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用
CN105130959B (zh) * 2015-09-18 2018-08-03 上海吉铠医药科技有限公司 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN107522695B (zh) * 2016-06-21 2018-09-14 上海方予健康医药科技有限公司 一种pim激酶抑制剂的盐酸盐及其制备方法和用途
CN107519175A (zh) * 2016-06-21 2017-12-29 上海方予健康医药科技有限公司 一种嘧啶化合物或其盐在制备用于预防和/或治疗与flt3相关的疾病或障碍的药物中的应用
CN107522696B (zh) * 2016-06-21 2019-02-19 上海方予健康医药科技有限公司 一种嘧啶类化合物的盐酸盐及其制备方法和用途
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US11236048B2 (en) 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
PL3746429T3 (pl) 2018-01-30 2022-06-20 Incyte Corporation Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu)
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US20210113562A1 (en) 2018-04-13 2021-04-22 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
EP3924351A4 (en) 2019-02-12 2022-12-21 Sumitomo Pharma Oncology, Inc. FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS
CN110078706B (zh) * 2019-05-31 2022-02-01 浙江师范大学 一种伊马替尼衍生物及其制备方法和用途
CN110452164B (zh) * 2019-09-10 2022-07-22 上海皓鸿生物医药科技有限公司 Pim447关键中间体的制备方法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
JP2022553832A (ja) * 2019-11-07 2022-12-26 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112915086B (zh) * 2021-01-27 2022-04-12 广州市力鑫药业有限公司 一种含有Akt靶向激酶抑制剂的药物组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251134A4 (en) 2000-01-26 2003-01-29 Meiji Seika Kaisha NEW CARBAPENEM DERIVATIVES OF THE QUATERNARY SALT TYPE
EP1257536A1 (en) * 2000-01-27 2002-11-20 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
JP2007513184A (ja) 2003-12-04 2007-05-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なキノキサリン
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20060004197A1 (en) 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
CA2617557A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
WO2007044724A2 (en) 2005-10-06 2007-04-19 Exelixis, Inc. Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
HRPK20050957B3 (en) * 2005-11-11 2008-09-30 Džanko Nikša Collapsible hanger
CA2668255A1 (en) * 2006-10-31 2008-05-08 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
CN101578275A (zh) * 2006-10-31 2009-11-11 先灵公司 苯胺基哌嗪衍生物及其使用方法
BRPI0808523A2 (pt) * 2007-03-01 2014-08-19 Novartis Vaccines & Diagnostic Inibidores de pim cinase e métodos de seu uso
JP5241834B2 (ja) * 2007-07-19 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての複素環アミド化合物
EP2195286A2 (en) 2007-09-10 2010-06-16 Cipla Limited Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
UY31679A1 (es) * 2008-03-03 2009-09-30 Inhibidores de cinasa pim y metodos para su uso
PT2344474E (pt) * 2008-09-02 2015-12-28 Novartis Ag Derivados de picolinamida como inibidores de cinase
US8809380B2 (en) 2009-08-04 2014-08-19 Raqualia Pharma Inc. Picolinamide derivatives as TTX-S blockers
EP2665711A1 (en) 2011-01-21 2013-11-27 Abbvie Inc. Picolinamide inhibitors of kinases

Also Published As

Publication number Publication date
HN2011000629A (es) 2015-08-10
AU2009289319C1 (en) 2013-12-05
BRPI0918268A2 (pt) 2020-11-17
HUE026381T2 (en) 2016-06-28
HRP20151410T1 (hr) 2016-01-15
MA32684B1 (fr) 2011-10-02
JP2012501314A (ja) 2012-01-19
US20120134987A1 (en) 2012-05-31
ES2551900T3 (es) 2015-11-24
MX2011002365A (es) 2011-04-04
CN103333157A (zh) 2013-10-02
SI2344474T1 (sl) 2015-12-31
EP2344474B1 (en) 2015-09-23
CN104311480A (zh) 2015-01-28
JP5813701B2 (ja) 2015-11-17
JP2013231049A (ja) 2013-11-14
IL211291A0 (en) 2011-04-28
US8329732B2 (en) 2012-12-11
US8592455B2 (en) 2013-11-26
CN102203079A (zh) 2011-09-28
US20140079693A1 (en) 2014-03-20
JP5412519B2 (ja) 2014-02-12
CO6351725A2 (es) 2011-12-20
NI201100052A (es) 2011-09-03
KR101345920B1 (ko) 2014-02-06
ECSP11010859A (es) 2011-04-29
GEP20135849B (en) 2013-06-10
KR20110048585A (ko) 2011-05-11
WO2010026124A1 (en) 2010-03-11
CA2734415A1 (en) 2010-03-11
AU2009289319A1 (en) 2010-03-11
SV2011003849A (es) 2011-07-07
PL2344474T3 (pl) 2016-03-31
DK2344474T3 (en) 2015-12-14
US20100056576A1 (en) 2010-03-04
EP2344474A1 (en) 2011-07-20
PT2344474E (pt) 2015-12-28
US9079889B2 (en) 2015-07-14
HK1162022A1 (en) 2012-08-17
TWI434843B (zh) 2014-04-21
SMT201600005B (it) 2016-02-25
EA020136B1 (ru) 2014-08-29
CA2734415C (en) 2016-07-26
US20150315150A1 (en) 2015-11-05
AU2009289319B2 (en) 2011-10-27
HK1156627A1 (en) 2012-06-15
ZA201101118B (en) 2011-09-28
MY150136A (en) 2013-11-29
CR20110114A (es) 2011-05-10
IL211291A (en) 2014-05-28
DOP2011000067A (es) 2017-01-15
NZ591449A (en) 2012-12-21
PE20110298A1 (es) 2011-05-21
BRPI0918268B1 (pt) 2021-08-03
ME01291A (me) 2013-06-20
CN102203079B (zh) 2014-12-10
TW201028393A (en) 2010-08-01
RS54506B1 (en) 2016-06-30
CL2011000454A1 (es) 2011-09-30
UY32085A (es) 2010-03-26

Similar Documents

Publication Publication Date Title
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
EA201100426A1 (ru) Бициклические ингибиторы киназы
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
MX2010010317A (es) Compuestos heterociclicos novedosos y usos de los mismos.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ECSP088823A (es) Quinazolinas para la inhibición de pdk1
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CY1113680T1 (el) Ενωσεις πυραζινης ως αναστολεις φωσφοδιεστερασης 10
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
MX2009013077A (es) Derivados dde benzoxazolona.
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
MX2010001813A (es) Metodos y composiciones para el tratamiento de canceres.
EA201101041A1 (ru) Производные пиридазинона
BR112013009260A2 (pt) compostos de carboxamida de piridazina substituídos como compostos inibidores de quinase
MX2011007232A (es) Derivados de benzotiazolona.
UA94055C2 (en) Substituted benzimidazoles and methods of preparation
JO3055B1 (ar) مشتقات بيكوليناميد كمثبطلت كيناز
TN2011000070A1 (en) Picolinamide derivatives as kinase inhibitors
CU20110043A7 (es) Derivados de picolinamida como inhibidores de cinasa

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ MD

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): TJ TM

TK4A Corrections in published eurasian patents
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ